SCHEMBL8977847

SCHEMBL8977847

COC(=O)c1cccc(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.47
PARP1 P09874 1/20 0.40
BRD4 O60885 1/20 0.40
PDE5A O76074 3/20 0.39
CYP1A2 P05177 3/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ABL1 P00519 1/20 0.38
ADORA2A P29274 1/20 0.38
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE1C Q14123 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467379 0.88 MRGPRX4 (0.49) MRGPRX4BRD4PDE5APDE1APDE1B
SCHEMBL8260068 0.81 MRGPRX4 (0.51) MRGPRX4PARP1BRD4CYP1A2MAPT
SCHEMBL8777276 0.78 KCNH2 (0.41) CYP3A4SMN1; SMN2
SCHEMBL22002661 0.77 MRGPRX4 (0.58) MRGPRX4PARP1BRD4CYP1A2MAPT
SCHEMBL31288949 0.77 PDE5A (0.61) MRGPRX4PDE5APDE1APDE1BPDE1C
SCHEMBL9174404 0.76 SMN1; SMN2 (0.42) NPC1RAB9ASMN1; SMN2
SCHEMBL30746942 0.76 MAPK1 (0.46) MAPTNPC1RAB9ASMN1; SMN2ABL1
SCHEMBL7479219 0.76 MEN1 (0.40) PDE5AGAANPC1CYP2C9RAB9A
SCHEMBL4134240 0.75 KCNH2 (0.38) CYP3A4SMN1; SMN2ABL1
SCHEMBL5466687 0.75 MRGPRX4 (0.55) MRGPRX4PARP1BRD4CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559134-A Leukotriene-B4 antagonists, process for their production and their use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1996-09-24 US disclosed